Maxime Dely – The French Transfusion landscape is Evolving
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The French transfusion landscape is evolving
As hospital needs change and health sovereignty becomes a national priority, the 2024 Annual Report of the French Blood Establishment (EFS) highlights a major transformation in the countryโs transfusion system.
Red blood cell use continues to decline
The number of red blood cell (RBC) units issued keeps decreasing:
- 2,081,938 units delivered in 2024
- -3.4 % compared to 2023
This trend reflects:
โข More efficient use of transfusion indications
โข Improved patient blood management
โข Optimization of clinical practices
Plasma takes center stage
Conversely, plasma collection is growing rapidly:
- 867,127 liters of plasma for fractionation delivered in 2024 (+4.8%)
- +1.4 % plasma donors in one year
This growth supports the national strategy โAmbition Plasmaโ, with an ambitious goal:
1.4 million liters of plasma collected per year by 2028
To reach this target, EFS is:
โข Progressively shifting from whole blood to plasma donations,
โข Opening new donation centers and time slots,
โข Expanding remote medical supervision (tele-assistance) to facilitate apheresis donations.
A strong and encouraging donor engagement
In 2024:
- 1,506,534 donors – including 17 % new donors
- 29 % under 30 years old – a promising new generation of donors
- A strong sense of commitment that secures the future of blood and plasma supply
The generational renewal is a key success factor for sustaining the transfusion system in the years to come.
A structural shift
2024 confirms a deep transformation:
- Fewer red blood cell transfusions
- More plasma collected, better utilized, and more strategic than ever
A crucial evolution to meet therapeutic needs, strengthen the national supply of plasma-derived medicines, and support France’s health sovereignty.
What’s next?
How can we accelerate this transition while maintaining donor loyalty and the right balance between all blood components?
Iโd love to hear your insights, experiences, and perspectives.”
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors
-
Dec 16, 2025, 16:50Raul Santos on Sex-Specific Biology and Plasma Fructose Levels in Cardiovascular Risk
-
Dec 16, 2025, 16:34Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
-
Dec 16, 2025, 16:22Leonardo Furtado Freitas Presents a Rare Hemorrhagic Hemangioblastoma Case
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms